Delving into the Latest Updates on Fluticasone furoate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Aramisuto, Arnuity Ellipta, Fluticasone furoate (JAN/USAN/INN)

+ [15]

Target

GR

Action

agonists

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesOtorhinolaryngologic Diseases+ [1]

Active Indication

AsthmaPulmonary Disease, Chronic ObstructiveRhinitis, Allergic, Perennial+ [2]

Inactive Indication

Acute sinusitisairway diseaseAllergic asthma+ [13]

Originator Organization

GSK Plc

Active Organization

GlaxoSmithKline Trading Services Ltd.

GSK PlcGlaxo Wellcome UK Ltd.

+ [4]

Inactive Organization

Glaxo Group Ltd.GlaxoSmithKline Research & Development Ltd.GlaxoSmithKline Research & Development

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (16 Jun 2000),

Rhinitis, Allergic

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC27H29F3O6S

InChIKeyXTULMSXFIHGYFS-VLSRWLAYSA-N

CAS Registry397864-44-7

Efficacy and Safety of Single-Inhaler Triple Therapy (SITT) of Fluticasone Furoate, Umeclidinium and Vilanterol inhalation (50 mcg/31.25 mcg/12.5 mcg) Metered dose inhaler (MDI) versus SITT of TRELEGY ELLIPTA, Dry powder inhaler (DPI) [Fluticasone Furoate, Umeclidinium and Vilanterol Powder for oral inhalation (100 mcg/62.5 mcg/25 mcg)] in Chronic Obstructive Pulmonary Disease (COPD) participants: A Multi-center, Randomized, Open-label, Comparative, Parallel Group Study. - NIL

Start Date20 Apr 2026

Sponsor / Collaborator

Lupin Ltd

CTRI/2026/04/107503

/ Not yet recruitingPhase 4

Randomized, Open-label, Comparative Study to Evaluate the Efficacy and Safety of Once-Daily Vilanterol / FluticaSone Furoate (Vi/FF) versus TWIce-Daily FormoTerol/Budesonide (For/Bud) MART in Patients with UnControlled AstHma: V-SWITCH study - V-SWITCH

Start Date15 Apr 2026

Sponsor / Collaborator

Glenmark Pharmaceuticals Ltd.

CTRI/2025/12/098826

/ RecruitingPhase 4

A prospective, open label, single-arm, multicentre, phase IV clinical trial to assess efficacy and safety of Vilanterol,Glycopyrronium and Fluticasone furoate powder for Inhalation in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) - NIL

Start Date20 Dec 2025

Sponsor / Collaborator

Zydus Healthcare Ltd.

100 Clinical Results associated with Fluticasone furoate

Login to view more data

100 Translational Medicine associated with Fluticasone furoate

Login to view more data

100 Patents (Medical) associated with Fluticasone furoate

Login to view more data

1,801

Literatures (Medical) associated with Fluticasone furoate

01 Sep 2026·CLINICAL OTOLARYNGOLOGY

A Novel Device to Improve the Tolerability of Intranasal Corticosteroid Sprays for Allergic Rhinitis and Postoperative Chronic Rhinosinusitis: A Crossover Trial

Article

Author: Douglas, Richard ; Ranasinghe, Sethmi ; Kimita, Wandia ; Berger, Xenia ; Biswas, Kristi ; Kim, Raymond

ABSTRACT:

Background:

Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are commonly treated with intranasal corticosteroid sprays. Despite their efficacy, unpleasant sensations associated with their application, including post‐nasal drip and nasal irritation, are often cited as reasons for poor compliance. Optimising the intranasal application experience is key to improving long‐term adherence. We developed a nasal adaptor for metered‐dose inhalers (MDIs) to reduce the unpleasantness of nasal administration, potentially improving patient compliance.

Methods:

Two crossover trials were conducted in AR and postoperative CRS participants ( n = 16 per group). Participants used a standard fluticasone nasal spray (50 μg) and a fluticasone MDI (125 μg) with the adaptor for 3 weeks each, separated by a 1‐week washout period. Device order was alternated, and doses were adjusted to ensure an approximately equal fluticasone dose. Device preference was determined using an adjusted Clinical Trial Patient Preference Questionnaire, and symptom improvement was assessed using Total Nasal Symptom Score and Sino‐nasal Outcome Test‐22 questionnaires.

Results:

Symptom improvement was comparable between the devices. However, in both groups, 11/16 (69%) participants preferred the MDI with the adaptor over the standard nasal spray, citing fewer unpleasant sensations. Satisfaction score improvement was significantly greater with the novel device in the CRS cohort. Participants reported a higher likelihood of compliance with the novel device, suggesting improved adherence.

Conclusions:

An MDI with the adaptor was preferred over a standard nasal spray among AR and postoperative CRS participants. The enhanced tolerability may promote improved compliance, and consequently, more effective long‐term symptom control.

01 Sep 2026·The journal of allergy and clinical immunology. Global

Effect of once-daily ICS/LAMA/LABA triple therapy versus ICS/LABA on respiratory symptoms (E-RS: Asthma): Analysis of the phase IIIA CAPTAIN trial

Article

Author: Oppenheimer, John ; Kerstjens, Huib A M ; Pizzichini, Emilio ; Papi, Alberto ; Slade, David ; Brusselle, Guy ; Moore, Alison ; Pavord, Ian D ; Yuanita, Liza ; Crawford, Jodie ; Inoue, Hiromasa

Background:

Addition of the long-acting muscarinic antagonist umeclidinium (UMEC) to the inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA) combination fluticasone furoate/vilanterol (FF/VI) improved lung function in adults with uncontrolled moderate to severe asthma in the CAPTAIN (Clinical study of Asthma Patients receiving Triple therapy through A single INhaler) study; however, the impact on symptoms requires further investigation.

Objective:

We sought to evaluate the effect of adding UMEC to FF/VI on asthma symptoms.

Methods:

The CAPTAIN study was a phase IIIA, randomized, controlled, 24- to 52-week study of patients with uncontrolled moderate to severe asthma despite ICS/LABA receiving once-daily single-inhaler FF/VI (100/25 or 200/25 μg) or FF/UMEC/VI (100/31.25/25, 100/62.5/25, 200/31.25/25, or 200/62.5/25 μg). Here, we compare the effect of pooled FF/UMEC 62.5/VI (100/62.5/25 and 200/62.5/25 μg) versus FF/VI (100/25 and 200/25 μg) on symptom control using prespecified analyses of change from baseline in Evaluating Respiratory Symptoms in Asthma (E-RS: Asthma) total and domain scores, and proportion of patients meeting an E-RS: Asthma total score responder threshold. We also performed post hoc analyses assessing the impact of baseline type 2 inflammation status on treatment response.

Results:

Least-squares mean (95% CI) reductions from baseline in E-RS: Asthma total score exceeded the minimum clinically important difference (-2.0 units) and were numerically greater with FF/UMEC 62.5/VI (-2.89 [-3.15 to -2.64]; n = 814) versus FF/VI (-2.47 [-2.73 to -2.22]; n = 813). The proportion of responders (45% [n = 360] vs 41% [n = 327]) and odds of response (odds ratio, 1.18 [95% CI, 0.96 to 1.45]) were numerically greater with FF/UMEC 62.5/VI versus FF/VI. Similar trends were observed irrespective of type 2 status.

Conclusions:

Patients with symptomatic asthma may benefit from optimized treatment interventions, such as adding a long-acting muscarinic antagonist to ICS/LABA.

01 Aug 2026·CLINICAL AND EXPERIMENTAL ALLERGY

Comparison of Allergic Rhinitis Treatments on Utilities and Quality of Life: A MASK ‐air Study

Article

Author: Lourenço‐Silva, Nuno ; Pereira, Ana Margarida ; Amaral, Rita ; Fonseca, João A. ; Zuberbier, Torsten ; Regateiro, Frederico S. ; Vecillas, Leticia de las ; Brussino, Luisa ; Giovannini, Mattia ; Taborda‐Barata, Luís ; Kvedariene, Violeta ; Samolinski, Boleslaw ; Marques‐Cruz, Manuel ; Larenas‐Linnemann, Desiree E. ; Sousa‐Pinto, Bernardo ; Klimek, Ludger ; Sastre, Joaquin ; Ventura, Maria Teresa ; Papadopoulos, Nikolaos G. ; Gemicioglu, Bilun ; Pfaar, Oliver ; Bognanni, Antonio ; Toppila‐Salmi, Sanna K. ; Valiulis, Arunas ; Vieira, Rafael José ; Coutinho‐Almeida, João ; Pham‐Thi, Nhân ; Bousquet, Jean

ABSTRACT:

Background:

Allergic rhinitis displays a relevant impact on quality of life. Medications used in the treatment of rhinitis have been assessed on their impact on rhinoconjunctivitis‐related quality of life, but not on generic health‐related quality of life metrics, such as utilities or EQ‐5D visual analogue scale (VAS) levels. This study aimed to compare different medication classes and individual medications on utilities and EQ‐5D VAS levels using data from a mobile app.

Methods:

We conducted an observational study using direct patient data from the MASK‐air mobile application, collected between May 2015 and December 2024. We compared rhinitis medication classes and individual medications on health utilities (computed from the EQ‐5D‐5L questionnaire) and the EQ‐5D VAS. To account for confounding, we employed inverse probability treatment weighting based on propensity scores, adjusting for demographics, baseline symptom control, and asthma status.

Results:

The study analysed 69,973 observations with EQ‐5D VAS data and 842 observations with utility data. At the medication class level, fixed combinations of intranasal antihistamines and corticosteroids were associated with improvements in EQ‐5D VAS (mean difference = 1.900; 95% CI = 1.316–2.484) and utilities (mean difference = 0.022; 95% CI = −0.015 to 0.059) compared with oral antihistamines (OAH). Intranasal antihistamines were associated with lower EQ‐5D VAS and utility scores than other intranasal treatments. For individual medications, mometasone was associated with a lower EQ‐5D VAS than budesonide and fluticasone furoate, while fexofenadine and levocetirizine tended to be associated with lower VAS values than other OAH.

Conclusion:

Fixed combinations of intranasal antihistamines and corticosteroids were associated with better quality‐of‐life than oral antihistamines and intranasal antihistamines. These findings could support future cost‐effectiveness analyses.

46

News (Medical) associated with Fluticasone furoate

11 May 2026

·www.biospace.com

Transpire Bio’s ANDA for Generic High-Strength Trelegy® Ellipta® Accepted for Filing by the U.S. FDA

SUNRISE, Fla. , May 11, 2026 /PRNewswire/ -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for fluticasone furoate, umeclidinium, and vilanterol inhalation powder, a generic version of the high-strength Trelegy ® Ellipta ®1 (200 mcg/62.5 mcg/25 mcg) product, has been accepted for filing by the U.S. Food and Drug Administration (FDA). Based on the FDA's public records, 2 Transpire Bio believes that it was the first company to ANDA for the high-strength product with a Paragraph IV certification under the provisions of the Hatch-Waxman Act. Should Transpire Bio's ANDA be approved by the FDA, Transpire Bio believes it will be eligible for 180 days of market exclusivity. In the U.S., Trelegy ® Ellipta ® is indicated for the maintenance treatment of asthma in patients 18 years and older and the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). According to IQVIA, Trelegy ® Ellipta ® reported U.S. annual sales of $8 Billion in 2025. 3 "The FDA's acceptance of our ANDA filing for the substitutable generic version of high-strength Trelegy ® Ellipta ® is another major milestone in advancing our development program and our complex generic franchise as a whole," said Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio. "Our highly experienced team in South Florida continues to meet and exceed each challenge put in front of them. With our first two ANDAs for generic Breo ® and Trelegy ® now confirmed as first-to-file, and this ANDA as our potentially third first-to-file, we move one step closer to providing patients suffering from asthma or COPD with an affordable option and improved access to this critical medication." "This milestone demonstrates Transpire Bio's strong capabilities in developing complex drug device combination products. We are extremely proud of the deep scientific and technical competence of our Transpire Bio team to constantly execute against our strategic plan," said Dr. Abhishek Gupta, Chief Scientific Officer of Transpire Bio. In addition to its focused complex generic franchise, Transpire Bio is building a pipeline of innovative inhalation medicines for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF), with three assets in development. Transpire Bio is also developing therapies for Pulmonary Arterial Hypertension (PAH), Diabetes, Obesity, Parkinson's Disease Psychosis, and Glioblastoma. These products are being developed and manufactured in Transpire Bio's state-of-the-art manufacturing facilities located in South Florida, U.S. Trelegy ® Ellipta ® is a registered trademark of the GSK group of companies. FDA’s “Paragraph IV” patent certification list IQVIA NPA (US SMART Edition). Data on file. About Transpire Bio Inc. Transpire Bio Inc. is an integrated US-based, clinical-stage biopharmaceutical company headquartered in Sunrise, Florida. Transpire Bio is innovating by applying its deep inhalation drug formulation and delivery expertise to respiratory and systemic diseases where currently available options are significantly lacking. Transpire Bio has developed multiple proprietary inhalation technology platforms, including dry-powder inhalers and soft-mist inhalers, and is progressing a pipeline of innovative inhalation medicines for Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (PPF), Pulmonary Arterial Hypertension (PAH), Diabetes, Obesity, Parkinson's Disease Psychosis, and Glioblastoma. For more information, please visit . View original content to download multimedia: SOURCE Transpire Bio

03 Mar 2026

·www.einpresswire.com

FDA approves first generic of Flovent HFA for treatment of asthma

[3/3/2026] Today, the U.S. Food and Drug Administration approved the first generic of Flovent HFA (fluticasone propionate) inhalation aerosol, 44 micrograms per actuation, for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. Flovent HFA is an inhaled corticosteroid used as maintenance treatment for asthma. It works by reducing inflammation in the lungs, helping to prevent asthma symptoms such as wheezing and shortness of breath. "Today's approval of the first generic fluticasone propionate inhalation aerosol represents an important step in expanding access to affordable asthma treatment," said Iilun Murphy, M.D., Director of the Office of Generic Drugs in the FDA's Center for Drug Evaluation and Research. "Generic medications provide patients with safe, effective, and more affordable treatment options. The FDA remains committed to facilitating the development and approval of generic drugs to increase patient access to essential medicines." Asthma affects almost 25 million Americans , 4.6 million of whom are children. There are an estimated 10 million asthma attacks per year, and 3,500 children and adults die each year from asthma. By making available a generic fluticasone propionate inhalation aerosol product, FDA has provided clinicians and the American public another available and valuable treatment option. “Between 5 and 10% of Americans and just over 6% of children have an asthma diagnosis. Flovent is a highly effective preventive medication, which, when used regularly, has been linked to a reduction in asthma-related hospitalizations and admissions to intensive care. As of today, with the approval of the first generic metered dose inhaler form of the medication we anticipate increased availability and reduced costs of treating this prevalent and at times very serious condition” says Acting Director or CDER, Tracy Beth Høeg, M.D., Ph.D. “I am proud of the work CDER has done to bring this generic to market.” The prescribing information for the generic fluticasone propionate inhalation aerosol includes the same contraindications, warnings, and precautions as Flovent HFA. Fluticasone should not be used as a primary treatment in status asthmaticus or in other acute episodes of asthma requiring intensive measures or in people with hypersensitivity to any of the product components. Fluticasone carries warnings such as oropharyngeal candidiasis and immunosuppression. The prescribing information should be consulted for a full description of warnings and precautions and adverse effects associated with the drug. The FDA granted approval of fluticasone propionate inhalation aerosol to Glenmark Specialty SA. Please contact the manufacturer for information about the medicine’s availability. Flovent HFA is a registered trademark of GlaxoSmithKline. For more information about generic drugs, visit https://www.fda.gov/drugs/buying-using-medicine-safely/generic-drugs . Content current as of: 03/03/2026 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

20 Feb 2026

·www.pharmaceutical-technology.com

Ex-Trump official-ran Altesa secures $75m in Series B funding round

Altesa will now progress its antiviral to a mid-stage trial. Credit: Kateryna Kon/ShutterStock.com Altesa BioSciences has closed an oversubscribed $75m Series B funding round to advance the clinical development of its antiviral, vapendavir. With funding from lead investor Forbion, as well as contributions from Sanofi and other venture capitalists, Altesa will progress vapendavir to Phase IIb trials in rhinovirus, a disease widely known as the common cold. Under the co-leadership of former US assistant health secretary, Brett Giroir and ex-GSK chief medical officer (CMO), Dr Katharine Knobil, the biotech will initiate the multinational CARDINAL study, which aims to enrol 900 patients with chronic obstructive pulmonary disease (COPD) to evaluate how treatment with vapendavir may impact the severity of rhinoviral-driven exacerbations within the disease. The trial is expected to begin in Q2 2026. According to Altesa, vapendavir could have the potential to prevent “up to 50% of COPD exacerbations” by stopping the common cold from infecting and reproducing within a host’s cells. The American Lung Association (ALA) currently cites respiratory diseases like cold and flu as the most common cause of exacerbations in COPD. Alongside its potential to reduce exacerbations, Knobil hopes that vapendavir can improve symptoms and maintain patient quality of life, while hastening the resolution of illness and potentially allowing patients to avoid advanced medical intervention. Vapedavir will head to Phase IIb with positive early-stage data under its belt, as the antiviral was found to diminish illness duration, inflammatory markers and both upper and lower airways symptoms in the Phase I Challenge study (NCT05962645). GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence COPD market takes a breath of fresh air Until recently, the COPD market was dominated by inhaled small molecule therapies, with combination options like GSK’s Telegy Ellipta (fluticasone furoate, umeclidinium bromide and vilanterol trifenatate) securing a strong share of the indication’s sales. However, the COPD approval of Sanofi and Regeneron’s biologic, Dupixent (dupilumab) as an add-on maintenance therapy marked the start of a biologics revolution – with GSK’s Nucala (mepolizumab) following in Dupixent’s footsteps in May 2025 and several candidates making their way through clinical trials. According to GlobalData’s Pharmaceutical Intelligence Center, there are currently 15 ongoing clinical trials evaluating eight biologics in COPD. GlobalData, the parent company of Pharmaceutical Technology , forecasts that the COPD market will be worth $30.2bn in 2033 .

Phase 2Drug ApprovalPhase 1

100 Deals associated with Fluticasone furoate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06315	Fluticasone furoate	R03BA09 R01AD12	DB08906

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Asthma	United States	GlaxoSmithKline Intellectual Property Development Ltd.	20 Aug 2014
Pulmonary Disease, Chronic Obstructive	Australia	GSK Plc	17 Apr 2014
Rhinitis, Allergic, Perennial	Canada	GSK Plc	22 Oct 2007
Rhinitis, Allergic, Seasonal	Canada	GSK Plc	22 Oct 2007
Rhinitis, Allergic	China	Glaxo Wellcome UK Ltd.	16 Jun 2000

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Tracheitis	Phase 3	Denmark	GSK Plc	03 Jul 2015
Bronchitis, Chronic	Phase 3	Czechia	GlaxoSmithKline Research & Development Ltd.	31 May 2012
Stiffness	Phase 3	Argentina	GSK Plc	30 Jun 2011
Stiffness	Phase 3	France	GSK Plc	30 Jun 2011
Stiffness	Phase 3	Germany	GSK Plc	30 Jun 2011
Stiffness	Phase 3	Italy	GSK Plc	30 Jun 2011
Stiffness	Phase 3	Norway	GSK Plc	30 Jun 2011
Stiffness	Phase 3	Russia	GSK Plc	30 Jun 2011
Stiffness	Phase 3	Ukraine	GSK Plc	30 Jun 2011
Cardiovascular Diseases	Phase 3	United States	GSK Plc	25 Jan 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ATS2026	Phase 3	Pulmonary Disease, Chronic Obstructive	572	single-inhaler ICS/LAMA/LABA triple therapy (TT)	dzmnpefwvt(xnjcledngy) = rkbiloxdmy drmtdqjiig (uhpcrbtyil, 129 - 173) View more	Positive	15 May 2026
				LAMA/LABA dual-therapy (DT)	dzmnpefwvt(xnjcledngy) = qltraukbyl drmtdqjiig (uhpcrbtyil, 130 - 167) View more
ATS2025	Phase 3	Asthma \| Inflammation Maintenance blood eosinophils \| fractional exhaled nitric oxide	-	Fluticasone Furoate/Umeclidinium/Vilanterol	mkvpittqnd(roemgopbui) = gvcxknohhg lsdvucbjru (jgaokzcokt )	-	16 May 2025
				Fluticasone Furoate/Vilanterol	mkvpittqnd(roemgopbui) = rqctpavncy lsdvucbjru (jgaokzcokt )
ATS2025	Phase 3	Pulmonary Disease, Chronic Obstructive	4,151	Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)	zlvptppegb(gwuhdbknst) = zfzggsffvm wqrjfpqvul (niswuolvdx ) View more	Positive	16 May 2025
				Fluticasone Furoate/Vilanterol (FF/VI)	zlvptppegb(gwuhdbknst) = xvlplsdtxp wqrjfpqvul (niswuolvdx ) View more
ATS2025	Phase 3	Asthma	-	FF/VI 100/25	mgmyghsvrc(kpbhnuzcwq) = rdqutxnrvv vxbbkievba (ralumphkpv )	Positive	16 May 2025
				FF/VI 200/25	mgmyghsvrc(kpbhnuzcwq) = lukydytemc vxbbkievba (ralumphkpv )
ELLITHE (ERS2024)	Not Applicable	Pulmonary Disease, Chronic Obstructive	617	Fluticasone furoate+Umeclidinium+Vilanterol	mqoxwphftx(nybuvtehze) = nekjkoodst jzwashvgho (wfxulbtgbh ) View more	Positive	07 Sep 2024
TARhiC (AAAAI2024)	Not Applicable	Rhinitis, Allergic, Perennial Maintenance	87	Fluticasone propionate/azelastine (FP/Aze 50/137 μg each nostril twice daily)	mwmdbflmok(uatajwjjmh): mean difference = 1.26 (95% CI, 0.59 - 1.93), P-Value = <0.001	Positive	23 Feb 2024
				Fluticasone furoate (FF 55 μg each nostril once daily)
ERS2023	Not Applicable	Pulmonary Disease, Chronic Obstructive	5,537	Multiple inhaler triple therapy (MITT)	nwknibnaqp(ybttsejipp) = ugludgzawy ibxdrettzj (zlmsckjfyc )	Positive	09 Sep 2023
ATS2023	Not Applicable	Asthma	-	Fluticasone Furoate/Vilanterol	bnpmtepimy(lonllbjhdn) = Similar proportions of participants experienced ≥1 on-treatment adverse event (AE) in both populations (5-17 year-olds: n=181/454 [40%] receiving FF/VI versus n=163/448 [36%] receiving FF; 5-11 year-olds: n=133/337 [39%] receiving FF/VI versus n=122/336 [36%] receiving FF) ycjgruqemx (ahojjuhkvb )	-	21 May 2023
NCT05736874 (CTgov)	Phase 3	COVID-19	1,407	Fluticasone (Arm C - Fluticasone)	jcpsgmokdn(ifwzpaqrnw) = tcwquzhxwi oqnibdhrwl (kxrrjxhrme, bdwpfbhzvt - pcanbqlenb) View more	-	12 Apr 2023
				Placebo (Arm C - Placebo)	jcpsgmokdn(ifwzpaqrnw) = ixswdxufod oqnibdhrwl (kxrrjxhrme, ignbkvptja - xijagicocc) View more
NCT02889809 (114971, CTgov)	Phase 4	Asthma \| Childhood asthma	477	Placebo+Montelukast	zewezxojkr(mevnmcwrif) = brkvqlireg kxkqonoejf (bnyobekvws, 0.1090) View more	-	04 Jan 2022